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The potential health and economic value of SARS-CoV-2 
vaccination alongside physical distancing in the UK: 
a transmission model-based future scenario analysis 
and economic evaluation
Frank G Sandmann, Nicholas G Davies, Anna Vassall, W John Edmunds, Mark Jit, on behalf of the Centre for the Mathematical Modelling of 
Infectious Diseases COVID-19 working group*
Summary
Background In response to the COVID-19 pandemic, the UK first adopted physical distancing measures in 
March, 2020. Vaccines against SARS-CoV-2 became available in December, 2020. We explored the health and 
economic value of introducing SARS-CoV-2 immunisation alongside physical distancing in the UK to gain insights 
about possible future scenarios in a post-vaccination era.
Methods We used an age-structured dynamic transmission and economic model to explore different scenarios of UK 
mass immunisation programmes over 10 years. We compared vaccinating 75% of individuals aged 15 years or older 
(and annually revaccinating 50% of individuals aged 15–64 years and 75% of individuals aged 65 years or older) to no 
vaccination. We assumed either 50% vaccine efficacy against disease and 45-week protection (worst-case scenario) or 
95% vaccine efficacy against infection and 3-year protection (best-case scenario). Natural immunity was assumed to 
wane within 45 weeks. We also explored the additional impact of physical distancing on vaccination by assuming 
either an initial lockdown followed by voluntary physical distancing, or an initial lockdown followed by increased 
physical distancing mandated above a certain threshold of incident daily infections. We considered benefits in terms of 
quality-adjusted life-years (QALYs) and costs, both to the health-care payer and the national economy. We discounted 
future costs and QALYs at 3·5% annually and assumed a monetary value per QALY of £20 000 and a conservative 
long-run cost per vaccine dose of £15. We explored and varied these parameters in sensitivity analyses. We expressed 
the health and economic benefits of each scenario with the net monetary value: QALYs × (monetary value per QALY) – costs.
Findings Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148·0 million 
(95% uncertainty interval 48·5–198·8) COVID-19 cases and 3·1 million (0·84–4·5) deaths would occur in the UK 
over 10 years. In the best-case scenario, vaccination minimises community transmission without future periods of 
increased physical distancing, whereas SARS-CoV-2 becomes endemic with biannual epidemics in the worst-case 
scenario. Ongoing transmission is also expected in intermediate scenarios with vaccine efficacy similar to published 
clinical trial data. From a health-care perspective, introducing vaccination leads to incremental net monetary values 
ranging from £12·0 billion to £334·7 billion in the best-case scenario and from –£1·1 billion to £56·9 billion in the 
worst-case scenario. Incremental net monetary values of increased physical distancing might be negative from a 
societal perspective if national economy losses are persistent and large.
Interpretation Our model findings highlight the substantial health and economic value of introducing SARS-CoV-2 
vaccination. Smaller outbreaks could continue even with vaccines, but population-wide implementation of increased 
physical distancing might no longer be justifiable. Our study provides early insights about possible future 
post-vaccination scenarios from an economic and epidemiological perspective.
Funding National Institute for Health Research, European Commission, Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In early 2020, physical distancing (or social distancing) 
measures were adopted in at least 149 countries in 
response to the widespread community transmission of 
SARS-CoV-2.1,2 Physical distancing measures included 
closures of schools, non-essential retail, hospitality venues, 
and workplaces; orders to stay at home and keep a distance 
of 1–2 m from individuals from different households; 
restrictions on mass gatherings and movement (including 
public transport); and isolation of symptomatic cases and 
quarantining of exposed indi viduals.2 The UK Government 
first adopted similar measures in March, 2020, following a 
rapid rise in cases of COVID-19 and the prospect of the 
health-care system becoming overwhelmed.3
The mandatory measures of physical distancing were 
implemented in the early stages of the pandemic on the 
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basis of the high transmissibility of SARS-CoV-2 and 
burden of COVID-19, uncertainties about COVID-19 
epidemiology,1 the absence of effective pharmaceutical 
interventions against COVID-19, and the imperative to 
save lives under the rule of rescue.4 Nonetheless, the 
pandemic response has led to large contractions of the 
global economy, and the largest contraction in the UK 
economy since monthly records began in 1997, with 
gross domestic product (GDP) falling by 5·8% in 
March, 2020, and by 20·4% in April, 2020,5 and being 
forecast to fall by 11% in 2020–21.6 So far, COVID-19 
and associated policy responses have cost the UK’s 
economy at least £280 billion in 2020–21, which is nearly 
14% of the annual GDP,6 without including the full 
macro-economic impact of both response and disease.
In terms of minimising health losses and economic 
harm, apart from continued non-pharmaceutical inter-
ventions such as physical distancing and extended testing 
and tracing for SARS-CoV-2 infection, effective and safe 
pharmaceutical interventions will be required. Vaccines 
provide a potential control strategy not requiring recurring 
lockdowns or extensive testing. As of March 12, 2021, 
WHO is tracking 182 vaccine candidates in preclinical 
evaluation and 81 candidate vaccines in clinical trials, of 
which 21 are in phase-3 trials.7 The first COVID-19 vaccine 
was authorised for temporary supply in the UK on 
Dec 2, 2020, with vaccination rollout starting on 
Dec 8, 2020.8,9 Further vaccines have since been authorised, 
and the UK has signed agreements for at least seven 
vaccine candidates and co-funded clinical trials.9 Therefore, 
we aimed to explore the health and economic value of 
introducing a SARS-CoV-2 immunisation programme in 
the UK. Given the unknown characteristics of the longer-
term epide miology of COVID-19, we focused on the wider 
impact of vaccination alongside physical distancing 
scenarios, as the value of vaccines will depend on other 




We used CovidM, an age-stratified dynamic transmission 
model that was developed to explore the effect of COVID-19 
and non-pharmaceutical interventions in the UK.10 In this 
susceptible-exposed-infectious-recovered epidemic model, 
individuals are stratified into 5-year age bands and 
susceptible individuals can become infected and move into 
an exposed compartment before becoming infectious and 
Research in context
Evidence before this study
We searched PubMed and medRxiv for economic evaluations of 
SARS-CoV-2 vaccines with the search string “(coronavirus OR 
COVID OR SARS-CoV-2) AND (vaccin* OR immunisation) AND 
((economic evaluation) OR (cost effectiveness analysis)) AND 
2020[dp]” on Sept 21, 2020, and last on Nov 29, 2020, with no 
language restrictions. We found one preprint publication that 
valued health outcomes in monetary terms and explored the 
additional impact of vaccines in a cost–benefit analysis of 
physical distancing for the USA, and a preprint that used a 
static Markov model to explore the cost-effectiveness of 
vaccines in the USA. No study focused on vaccines in a full 
economic evaluation using a dynamic modelling framework.
Added value of this study
With several vaccines being authorised for supply in the UK, our 
study is, to our knowledge, one of the first to explore the health 
and economic value of introducing a national SARS-CoV-2 
immunisation programme. A programme with high vaccine 
effectiveness and long-lasting protection might minimise 
community transmission without further need of increased 
physical distancing, but a vaccine with 50% efficacy against 
disease could still be worthwhile to use, even at short-lived 
natural and vaccine-induced protections. Smaller outbreaks 
could continue even with vaccines, but enforced population-
wide physical distancing measures might no longer be required. 
Voluntary physical distancing as a sole strategy risks large initial 
epidemic peaks, unless accompanied by highly effective 
immunisation. Compared with no vaccination, introducing 
vaccination leads to positive net monetary value across physical 
distancing scenarios in the best-case scenario from the 
health-care perspective, subject to the long-run vaccine price 
and cost-effectiveness of other treatments (eg, new drugs). 
The positive net monetary value in the worst-case scenario 
depends on the assumed vaccine price, discount rate, the 
monetary value assigned to quality-adjusted life-years, and 
continued physical distancing. The net monetary value of 
immunisation decreases if natural immunity is long or vaccine-
induced protection is short. Intermittent periods of increased 
physical distancing lead to negative net benefits from the 
perspective of the wider economy if the daily national income 
losses are persistent and larger than under less strict physical 
distancing scenarios.
Implications of all the available evidence
Our model findings highlight the substantial health and 
economic value of introducing SARS-CoV-2 vaccination 
alongside physical distancing measures to control the 
COVID-19 pandemic in the UK, with vaccines likely to achieve 
good value for money. Despite the many uncertainties, 
continued physical distancing might be needed to reduce 
community transmission until high population-wide coverage 
is achieved with vaccines that provide long-lasting protection 
against both disease and infection. Ongoing transmission is 
also expected in an intermediate scenario with partial efficacy 
against infection. Our study provides the first broad health-
economic insights about possible future scenarios in a 
post-vaccination era, and the value of vaccines will 
depend on other socioeconomic and health-related 
policies and population behaviours.
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symptomatic. A predefined proportion of individuals will 
be asymptomatically infected only. Individuals recover but 
natural protection can wane over time without affecting 
the assumptions of reinfections. Our estimated cases refer 
to symptomatic (clinical) cases. The model also tracks 
COVID-19-related hospital admissions and deaths by age; 
for more details, see the study by Davies and colleagues.10 
We also explored updating parameters using data from the 
UK (appendix pp 1–4).
We extended the compartmental model to investigate 
the health impact of an immunisation programme and 
the economic value of SARS-CoV-2 vaccination in the 
UK. Individuals who have been vaccinated move into 
separate compartments, assuming either total protection 
or no protection from infection and exponential waning 
of vaccine-induced protection over time; both of these 
assumptions are conservative given that vaccine trials 
have been done in settings with high force of infection9 
and duration of vaccine protection remains unclear.11,12 
The model structure was further adapted to also allow for 
protection against disease but not infection. We added 
demography in terms of births and (disease-unrelated) 
deaths, which allows the exploration of outcomes over 
10 years (2020–29) to sufficiently capture the potential 
effects of vaccination.
In late 2020, a new SARS-CoV-2 variant was detected in 
the UK and was estimated to have increased trans-
missibility by 43–90% (range of 95% credible intervals 
[CrIs] 38–130).13 Our model starts with a basic reproduction 
number, R0, of 2·7 (95% CrI 1·6–3·9), which was based on 
a previously derived consensus distribution of 11 published 
estimates.10 Hence, the uncertainty interval (UI) of the 
variation in R0 in our analysis overlaps with the estimated 
range of basic reproduction numbers of the new variant.13 
At the start of the model and for the first 6 months 
afterwards, five new infections are introduced into the 
population each day for 7 days in the age groups 
20–49 years to represent a low but continuous (undetected) 
importation of infections initially.14 In a sensitivity analysis, 
we limited the importation rate of new infections to the 
first 6 months, which would in theory allow elimination.
Immunisation programme intervention and 
comparator scenarios
The model compared three main scenarios: a no-
vaccination baseline scenario versus two vaccination 
programmes resembling the worst-case and best-case 
extremes of a reasonable spectrum of assumptions about 
vaccine characteristics that were partly informed by 
phase 3 trial data.9,15,16 The worst-case vaccination 
scenario assumed 50% vaccine efficacy15,17 and vaccine-
induced protection against disease (ie, symptomatic 
infection is replaced by asymptomatic infection with 
50% decreased transmissibility) of 45-week duration 
(similar to the assumed duration of natural immunity),18 
whereas the best-case vaccination scenario assumed 
95% vaccine efficacy8,9 and vaccine-induced protection 
against both symptomatic and asymptomatic infection 
of 3-year duration (assumed similar to the reported 
duration of immunity for SARS-CoV and MERS).11 In 
both vaccination scenarios, we assumed an uptake of 
75% in individuals aged 15 years or older and a targeted 
vaccination rollout according to the current UK 
prioritisation advice,19 and annual revaccination of 50% 
in individuals aged 15–64 years and of 75% in individuals 
aged 65 years or older (similarly to seasonal influenza 
vaccination). Natural protection from infection was 
assumed to wane within a mean of 45 weeks in the base 
case.18
In sensitivity analyses, we varied the duration of natural 
and vaccine-induced protection from 12 weeks to 5 years,11 
the age groups targeted with vaccination (including 
vaccinating uniformly across age groups), the initial 
vaccination rate before revaccination, the revaccination 
coverage, the timing of the vaccination introduction if 
delayed until the start of 2022, the vaccination uptake 
rate after the initial phase and before starting annual 
re-vaccinations, the impact of the imported cases each 
month, and the vaccine efficacy against disease or 
infection according to published clinical trial data.9,15,16
We assumed vaccination introduction starting from 
Dec 8, 2020, with protection assumed to start after 
28 days.8,9
Physical distancing scenarios
The model considered the vaccination scenarios with and 
without periods of increased physical distancing. Physical 
distancing was implemented by reducing the number of 
close contacts of individuals at home, work, school, and 
other locations (such as transport and leisure; appendix p 1) 
that could lead to transmission events. These effective 
reductions in transmission can be the result of personal 
non-pharmaceutical interventions such as keeping a safe 
physical space from individuals from other households, 
wearing face coverings (masks), and increased hand 
hygiene. However, these are less susceptible to government 
interventions and also have much lower societal costs, so 
we do not explicitly model their effects. We consistently 
assumed voluntary physical distancing of the public after 
the initial outbreak in all scenarios and for the remaining 
duration of the 10 years of the model, with close contacts 
being reduced by a third at work, school, and other 
locations. All physical distancing scenarios also considered 
summer and winter holidays, during which school 
contacts were reduced to 0 (appendix p 1). The model made 
no explicit assumptions about increased mixing between 
children from different schools and locations during 
holidays (eg, during play dates).
We explored three groups of physical distancing 
scenarios: no historical lockdown (a counterfactual 
scenario), an initial lockdown as observed historically (ie, 
up to mid-July), and an initial lockdown followed by 
intermittently occurring increased physical distancing 
where contact rates are reduced once incidence goes over a 
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certain level (varied in sensitivity analysis to be triggered 
at daily incidence levels of ten to 100 cases per 
100 000 population). The initial lockdown and increased 
physical distancing result in a similar scaling of the contact 
matrices (appendix p 1). Contacts are increased again once 
the daily incidence reaches fewer than 500 cases (about 
one case per 100 000). All simulations started on Jan 1, 2020, 
for 10 years to allow exploration of counterfactual scenarios.
Comparison of estimated with observed hospital 
admissions
For scenarios with an initial lockdown, the incidence 
threshold for the initial lockdown and start of voluntary 
physical distancing was based on aligning the estimated 
cumulative number of hospital admissions to the 
observed numbers in the UK as of July 15, 2020 
(appendix p 1), with an estimated 8·54% of the population 
having been infected by mid-July, 2020. Rather than 
reproducing the first few months of the pandemic 
precisely, however, we did not fit the model to the full 
range of data available given the many uncertainties and 
unknown characteristics of the vaccines and aspects of 
the COVID-19 epidemiology.
Health and economic impact
The economic analysis was fully integrated with the 
epidemiological model. Our main analysis adopted the 
reference case used to evaluate vaccines in the UK,20,21 
considering benefits in terms of disease prevented using 
quality-adjusted life-years (QALYs), and the costs from the 
perspective of the National Health Service (NHS) over a 
10-year timeframe. The main outcome was the net 
monetary value of each of the 27 combined vaccination 
and physical distancing scenarios, calculated by expressing 
the combined health (QALYs) and economic benefits of 
the interventions in monetary terms: QALYs × (monetary 
value per QALY) – costs.22 Net monetary values can be used 
to show which intervention minimises losses, since all 
scenarios have negative net monetary values (ie, they 
destroy economic value) compared with no pandemic. 
We assumed a monetary value per QALY of £20 000,20,21 
which we varied between £0 and £60 000 in a sensitivity 
analysis.23 Positive incremental net monetary values of 
vaccination against no vaccination thus indicate results 
within the chosen cost-effectiveness threshold (eg, £20 000 
per QALY), suggesting that the vaccination or physical 
distancing scenarios considered are cost-effective. 
Negative incre mental net monetary values indicate results 
above the cost-effectiveness threshold, suggesting that the 
scenarios considered are not cost-effective and are 
dominated by the comparator because of either minimal 
QALY gains at excessive additional costs or excessive 
QALY losses being insufficiently compensated for by 
minimal cost savings.22 Future costs and QALYs were 
discounted at 3·5% annually,20,21 and we explored varying 
the discount rate between 0% and 10% in a sensitivity 
analysis.20,23
To assess the health impact of the interventions, we 
considered the QALYs lost by sympto matic cases, non-
fatal hospital admissions, intensive care unit (ICU) 
survivors, post-acute (long) COVID, adverse events 
following immunisation, and premature fatalities due to 
COVID-19 (appendix pp 8–9). For the costs from 
the NHS perspective, we considered the expenditures on 
hospital admissions (ICU and non-ICU), enhanced 
personal protective equipment, visits to general practi-
tioners, remote helpline calls, adverse events following 
immunisation, vaccine adminis trations, and vaccine 
costs (appendix pp 9–11). We assumed a conservative 
long-run cost per vaccine dose of £15 (based on the first 
authorised vaccine in the UK; appendix p 10), which we 
varied in sensitivity analyses from £0 (ie, without 
assigning financial cost to the vaccine doses) to £50. 
Additional costs of setting up a delivery programme have 
not been included other than a public tender for ultra-low 
temperature freezers required by the first authorised 
vaccine (appendix pp 10–11). In addition, the vaccination 
scenarios included the public expenditures on sub-
sidising the development of SARS-CoV-2 vaccines with 
£250 million by the UK Government,24 which could be 
regarded as an extraordinary lump-sum ex-ante 
premium.
We did an exploratory, secondary analysis that consi-
dered the negative impact of physical distancing on the 
wider national economy, and the incremental benefit of 
introducing vaccination on that impact. This analysis can 
be used as a framework until more is known about 
the vaccines. We approximated the costs of physical 
distancing in terms of losses to the UK’s GDP, which is 
a monetary output measure of all goods and services 
produced in a country during a specific period. We 
assumed that daily GDP was £5757 million, based on the 
seasonally adjusted GDP in the fourth quarter of 2019 of 
£523 917 million,25 and we assumed national income 
losses from physical distancing and potentially other 
measures aiming to reduce transmission. GDP losses 
were conservatively assumed at the equivalent of 2% of 
daily GDP (ie, around £115·1 million) for each day 
COVID-19 incidence exceeded 1000 new reported cases 
while only voluntary physical distancing was in place 
(similar to the largest pre-COVID-19 reduction since 1997; 
the 1000 new reported cases were approximated by the 
numbers in mid-March, 2020).5 In addition, losses on 
days of the scenarios with an initial lockdown and 
subsequent increased physical distancing were evaluated 
against the same threshold. However, as the daily GDP 
loss might differ according to the physical distancing 
scenario (eg, losses could be higher when increased 
physical distancing is triggered by a lower incidence 
threshold), for scenarios with increased physical dis-
tancing, we additionally explored higher losses between 
the equivalent of 2% and 15% of daily GDP whenever 
increased physical distancing was imposed (including 
the fall in GDP of 5·8% over March, 2020, and the 
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forecasted 11% decrease in 2020–21).5,6 We did not add 
health sector costs estimated under the NHS perspective 
or productivity losses in COVID-19 cases to these wider 
economic costs, to avoid double counting. However, we 
considered QALY losses for this wider perspective, too, 
and presented results in terms of the net monetary value.
To account for parameter uncertainty, we ran the 
epidemiological model deterministically with R0 values 
of 2·7 (the base case) as well as 1·6 and 3·9.10 
The economic model used a probabilistic sensitivity 
analysis with 1000 iterations using Monte Carlo sampling 
(appendix p 8).
Role of the funding source
The funders of the study had no role in study design; 
data collection, analysis, and interpretation; preparation 
of the manuscript; or the decision to publish.
Results
An unmitigated epidemic without an initial lockdown 
is expected to have led to high incidence of infection in 
the initial outbreak (figure 1A), with smaller but 
recurring annual outbreaks due to varying contact rates 
and transmission during holidays, and loss of natural 
immunity and births replenishing the susceptible 
population. By contrast, implementing an initial lock-
down as observed historically moves the high burden 
into the second peak (figure 1B), with little change in 
the overall burden as compared with no lockdown over 
a 10-year period (figure 2A). Intermittent periods of 
increased physical distancing without vaccination 
(baseline scenario) could change the height of future 
peaks and split up the epidemic into two smaller 
outbreaks each year (figure 1C–F), with a consequent 
reduction in burden (figure 2A).
Figure 1: Epidemiological impact of SARS-CoV-2 vaccination in the UK over 10 years
Time-series of the daily number of symptomatic cases of COVID-19 in the UK for selected physical distancing scenarios and the three targeted vaccination scenarios (ages 15 years and older). 
Summer and winter holidays are shown in light blue and periods of increased physical distancing and initial lockdowns in light red. In vaccination scenarios, the dashed vertical line indicates the 
beginning of the vaccination programme. The x-axis starts on Jan 1, 2020. The y-axis is truncated at 100 000 cases daily to allow meaningful visual comparisons across panels. Not all physical 
distancing scenarios are shown for ease of presentation.
No lockdown Initial lockdown only
Incidence trigger of increased physical distancing: 10 cases per 100000 population
No vaccination
Incidence trigger of increased physical distancing: 20 cases per 100000 population













































































































































































































































































































































































     











     















     












     
     











     
     











     
     











     
     












     
     












     











     















     












     
     











     
     











     
     











     
     












     
     












     











     















     












     
     











     
     











     
     











     
     












     
     






 Increased physical distancing scenarios
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In the worst-case vaccination scenarios, introducing 
vaccination could lower and delay the peaks of future 
outbreaks, which is most apparent in the no lockdown 
and initial lockdown only scenarios (figure 1). Vaccines 
that are highly effective against disease and infection 
could reduce transmission to its lowest levels in the 
model within 3–4 years without further periods of 
increased physical distancing, while SARS-CoV-2 is 
likely to become endemic (figure 1). Ongoing trans-
mission is also expected in intermediate scenarios with 
vaccine efficacy against disease and infection similar to 
the published clinical trial data (appendix pp 16–17). A 
targeted vaccination strategy is more effective at 
reducing case numbers than vaccinating uniformly, 
even though the disease dynamics are similar (appendix 
p 18).
The 10-year burden of an unmitigated epidemic in 
the UK (the counterfactual scenario) was estimated 
as 148·0 million (95% UI 48·5–198·8) cases, 3·1 million 
(0·84–4·5) deaths, and 93·1 million (77·5–110·2 million) 
QALYs lost (figure 2; appendix pp 11–13). Combined 
with periods of increased physical distancing, these 
numbers can be reduced over the same time period to 
21·4–70·2 million cases, 0·39–1·3 million deaths, and 
12·4–41·5 million QALYs lost. Introducing vaccination 
is estimated to reduce these numbers further to 
12·1–65·4 million cases, 0·17–1·21 million deaths, and 
6·8–38·3 million QALYs lost. The estimated number of 
days in lockdown or with increased physical distancing 
is substantial, unless vaccines with high efficacy and 
long-lasting protection against infection become 
available (figure 2; appendix pp 11–12).
From the health-care perspective, the total costs of the 
COVID-19 pandemic in the UK over 10 years in the 
unmitigated scenario without vaccination or increased 
physical distancing amount to £85·6 billion (95% UI 
58·7 to 123·8) compared with a situation where the 
COVID-19 pandemic had never happened (figure 2; 
appendix pp 12–14). Without introducing vaccination, 
implementation of increased physical distancing tri-
ggered at different incidence levels decreases the 
costs by £4·7 billion up to £74·3 billion. Depending 
on the physical distancing scenario, introducing vacci-
nation increases total costs by £6·8–66·0 billion 
(figure 2B; appendix pp 12–14).
When considering health outcomes and costs through 
the net monetary value, losses from COVID-19 were 
highest for the unmitigated scenario, at £487 billion 
(95% UI 369–632; figure 2C). Compared with no 
vaccination, introducing vaccination leads to positive 
incremental net monetary values in the best-case 
scenario, ranging from £12·0 billion to £334·7 billion 
across physical distancing scenarios; however, in the 
worst-case scenario, incremental net monetary values 
ranged between –£1·1 billion and £56·9 billion 
(figure 2C; appendix pp 12–13). Incremental net 
monetary values were positive in all scenarios at a 
higher monetary value of a QALY (figure 3A), lower 
vaccine prices (figure 3B), or lower discount rates 
(appendix p 19).
The incremental net monetary value of introducing 
vaccination versus no vaccination is always positive 
across physical distancing scenarios from a wider 
economic perspective (figure 4). Greater losses of 
national income are expected with a lower (ie, stricter) 
incidence-rate threshold for physical distancing, 
leading to greater absolute net monetary losses from 
COVID-19 (figure 4).
In sensitivity analyses, we found that with a longer 
duration of natural immunity, the incremental eco-
nomic value of immunisation decreases, potentially 
becoming lower than no vaccination for long durations 
of natural immunity and 50% vaccine efficacy against 
disease (worse-case scenario; figure 5A). Similarly, with 
a longer duration of vaccine-induced protection against 
disease or infection, the economic value of vaccination 
compared with no vaccination increases (figure 5B). In 
the absence of reliable data, however, these findings 
merely illustrate the sensitivity of results to immunity 
assumptions, and the level of cross-protection to novel 
variants remains unclear (and thus supports assuming 
a shorter duration of immunity until more data become 
available). If the introduction of safe and effective 
vaccination had been delayed beyond December, 2020, 
the economic value was estimated to decrease in most 
scenarios (with a few exceptions at very strict physical 
distancing levels and depending on the size of the 
epidemic peak at the time of vaccine introduction; 
appendix p 20). The efficiency in terms of incremental 
net monetary value gained per vaccinated individual 
increased when targeting vaccines according to 
prioritisation groups and when vaccines are safe and 
effective to use in ages younger than 15 years; 
vaccinating uniformly across age groups was most 
efficient in terms of incremental net monetary value 
gained in individuals aged 65 years or older 
(appendix p 21). Increasing revaccination coverage 
increased the net monetary value in the best-case 
scenario only (appendix p 22). Findings were 
robust against the assumed initial daily vaccination rate 
before annual revaccination (appendix p 23) and the 
monthly infection importation rate (appendix p 24).
Figure 2: Health and economic impact of SARS-CoV-2 vaccination in 
the UK
Results show impacts over 10 years for different physical distancing scenarios 
and the three vaccination scenarios. Panel A shows the estimated numbers of 
cases, deaths, and days of increased physical distancing; panel B shows the 
total costs and QALYs lost; and panel C shows the net monetary value as costs 
due to COVID-19 from a health-care perspective. The uncertainty in panel A 
reflects the values of the 95% credible interval of R0 values used in the 
epidemiological model, whereas the uncertainty in panel B reflects the 
95% credible interval of the Monte Carlo sampling. QALYs=quality-adjusted 
life-years. *Net monetary values are negative due to health losses and costs 
from COVID-19.
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Increased physical distancing trigger: 100 cases per 100 000 population
Increased physical distancing trigger: 50 cases per 100 000 population
Increased physical distancing trigger: 20 cases per 100 000 population
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Figure 3: Value of QALYs and COVID-19 vaccine prices
Sensitivity analysis on the monetary value per QALY (A) and the price per vaccinated individual, assuming two doses (B), for selected physical distancing scenarios and the three vaccination scenarios. 
Losses are considered from a health-care perspective. Not all physical distancing scenarios are shown for ease of presentation. QALY=quality-adjusted life-year. *Net monetary values are negative due 
to health losses and costs from COVID-19.
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Discussion
This study explored the health and economic impact of 
introducing a SARS-CoV-2 vaccination programme in 
the UK. Our model findings show that highly effective 
vaccines with long-lasting protection against infection 
can reduce transmission over the next 10 years without 
recurring periods of increased physical distancing, while 
SARS-CoV-2 is likely to become endemic. Compared 
with no vaccination, introducing vaccination leads to 
positive net monetary value across physical distancing 
scenarios in the best-case scenario. Even in a worst-case 
scenario in which SARS-CoV-2 vaccines have 50% efficacy 
and provide only short-lived protection against disease, 
their use would still offer overall benefit at lower prices 
than £15 per dose, given the large health and economic 
costs of COVID-19. The value of the vaccine to the UK 
alone could be in the billions and possibly trillions of 
pounds. This indicates that investments in SARS-CoV-2 
vaccination have been worthwhile to accelerate the 
development of vaccine candidates at an unprecedented 
speed,1,26 and to make the vaccines available at accessible 
prices for both the UK and other countries, instead of 
competing at premium monopoly prices.
Within the framework of the analysis, our model 
results indicate the continued importance of physical 
distancing to reduce community transmission in 
the future, until population-wide vaccine coverage is 
sufficiently high. The analysis assumed a reduction of a 
third in non-home contacts in all scenarios that could 
lead to transmission events after the initial outbreak, due 
to people being more likely to continue working flexibly, 
businesses continuing to impose lower capacity limits on 
Figure 4: Wider economic impact of SARS-CoV-2 vaccination
The potential wider economic impact of vaccination in terms of net monetary values for different (proportions of) daily GDP loss during different physical distancing 
scenarios. Uncertainty reflects the 95% credible interval of the Monte Carlo sampling. GDP=gross domestic product. *Net monetary values are negative due to health 
losses and costs from COVID-19.
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Figure 5: Economic impact of natural and vaccine-induced protection
Sensitivity analysis on the economic impact of duration of natural protection (A) and vaccine-induced protection (B) against SARS-CoV-2 infection for selected physical distancing scenarios and the 
three vaccination scenarios. Losses are considered from a health-care perspective. *Net monetary values are negative due to health losses and costs from COVID-19. †Vaccine-induced protection kept 
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building occupancy, and continued precautionary 
behaviour by the public after more than a year of the 
pandemic, among other reasons. The value of periods of 
increased physical distancing in the worst-case scenario 
is even greater than reflected in the total QALYs and costs 
averted, since it splits annual epidemics into two separate 
peaks, which reduces the overall size of the peaks and 
hence the risk of exceeding hospital capacity. However, 
the intensity and economic cost of these subsequent 
periods of increased physical distancing might be 
less than those of the initial lockdowns, if they can 
be combined with other measures such as effective 
testing and contact tracing, improvements of treatment, 
better availability of personal protective equipment, and 
precautionary behaviour such as wearing face coverings 
and handwashing by the general population.
To our knowledge, this study is one of the first economic 
evaluations focusing on SARS-CoV-2 vaccination,27,28 and 
using established reference case methods.20,21 A few 
studies model the dynamics of SARS-CoV-2 vaccination 
(see, for example, Saad-Roy and colleagues29). Arguably, 
a conventional cost-effectiveness framework has its 
limitations during a pandemic: the monetary value 
per QALY could be different to the normal decision rules 
used in the UK given that (1) the value of alternative 
hospital admissions forgone when admitting COVID-19 
cases (ie, the opportunity costs of COVID-19 hospi-
talisations) is unclear, because alternative admissions 
being displaced are less well understood during a 
pandemic than, for example, during times of usual winter 
bed pressures;30 (2) we quantified the reduction in health 
loss and people generally prefer to avoid losses (loss 
aversion);31 and (3) the health opportunity costs will 
change with COVID-19 given that the overall health sector 
budget might shift and COVID-19 will have an impact on 
the efficiency of other health-care inter ventions. Some 
argue that a higher discount rate could be justified given 
that policy decisions before the emergence of SARS-CoV-2 
imply a relatively low value was placed on future non-
influenza pandemics.32 We also highlight the potential 
magnitude of broader societal benefit, but given that our 
methods are simple, and the need for further 
macroeconomic modelling, we did not explore other 
future research avenues such as which vaccine product 
provides best value for money using threshold pricing 
against a cost-effectiveness threshold or net societal 
benefit. Likewise, our modelling framework enables 
future research on the relative value of different observed 
combinations of vaccine characteristics, physical dis-
tancing scenarios, and vaccination strategies potentially 
including paediatric vaccination and revaccination, once 
more long-term real-world data have become available.
Our study has various strengths and limitations. 
We extended an age-structured dynamic-transmission 
model that was previously used to inform UK policies 
on introducing non-pharmaceutical interventions to 
provide early insights into the health and economic value 
of SARS-CoV-2 vaccination in the UK. Given the many 
uncertainties of the vaccine candidates and the longer-
term COVID-19 epidemiology, however, rather than 
reproduce the first few months of the pandemic precisely, 
we chose not to fit the model to the full range of data 
available. Modelling the counterfactual no-lockdown 
scenarios provide some useful context for policy makers 
on what has been observed in other jurisdictions outside 
the UK. Furthermore, the primary endpoint of many 
clinical trials for vaccines so far has focused on efficacy 
against symptomatic disease instead of infection, which 
can reduce the disease burden but might not prevent 
infection. When using a high R0 of 3·9, possibly 
corresponding to a scenario in which high-transmission 
variants have replaced original variants, the impact of 
vaccination is similar to the base-case analysis and does 
not change conclusions qualitatively. We also did not 
account for different risks of infection or infectivity by 
occupation or risk-group other than by age, and we did 
not include therapeutic pharmaceutical interventions 
that might not prevent transmission given our focus 
on vaccines (and which are unlikely to alter broad 
conclusions). Thus, the main aim of our analysis was to 
generate qualitative insights, not precise numbers.33
In an exploratory secondary analysis, our study also 
looked at the population-level trade-off in terms of health 
gains from disease averted versus costs to the economy. 
Although the modelled scenarios of physical distancing 
might not predict future disease dynamics for the next 
decade, physical distancing itself was not the focus of this 
study. However, ignoring the wider economic impact of 
physical distancing risks distorting conclusions as a 
lockdown might indeed help to reduce the health burden 
and health-care costs and thus look highly cost-effective 
from a health-care perspective, but it will harm the wider 
economy and society from a broader perspective. We also 
did not account for the economic impact of physical 
distancing causing long-term harm (such as reducing 
productivity) or conversely being mitigated by longer-
term structural change (such as shifts in employment 
towards economic sectors more resilient to physical 
distancing measures), that the actual GDP impact during 
the initial lockdown was mitigated in the UK by 
government actions that bear future cost implications, 
and that governments might become more efficient at 
minimising health loss versus economic trade-offs over 
time. Similarly, we did not account for future economic 
shocks. Although the analysis considered the impact for 
the UK population with 66·4 million individuals in 
England, Wales, Scotland, and Northern Ireland, the 
policy measures of physical distancing differ slightly 
between the four. Also, the study focused on the direct 
impact of COVID-19 and did not address growing 
concerns about inequality.
Additional factors that were not considered in this 
analysis might become important in the future, including 
enhanced testing programmes. Some of these effects 
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might have been included implicitly in our study by 
assuming long-term lower contact patterns of individuals 
following the first epidemic peak. Our economic analysis 
is also conservative in its input parameters, informing 
costs and quality-of-life values largely from other 
respiratory infections, but attempting to account for the 
impact of post-acute (long) COVID on quality of life.34 
Moreover, our study ignored indirect effects such as the 
health opportunity costs for displaced patients without 
COVID-19, potentially increased anxiety induced by 
COVID-19 in otherwise healthy individuals, excess 
mortality, the longer-term impact of both COVID-19 care 
and COVID-19-related physical distancing on other 
treatments (eg, delays in cancer care35), and other changes 
in demography (eg, on birth rates and perinatal 
outcomes). Similarly, the analysis assumes the same 
level of indirect herd effects from vaccines over 10 years, 
and might underestimate the impact of vaccination 
beyond 10 years. Both the COVID-19 pandemic and the 
SARS-CoV-2 vaccination programme might also disrupt 
health-care service delivery of other vaccination 
programmes,36–38 and possibly the disease dynamics of 
other close-contact infections.39 We were also unable to 
provide accurate estimates on the wider social 
opportunity costs arising from the longer-term impact on 
mental health, household finances, and education both 
at an individual and a societal level.32 Some of these 
difficulties stem from estimating how COVID-19 
interacts with feedback loops in the health system as an 
external shock and will need to be quantified later. 
Including these effects, however, is likely to increase the 
value of vaccination.
In conclusion, our findings highlight the health and 
economic value of introducing SARS-CoV-2 vaccination 
to control the COVID-19 pandemic. Continued physical 
distancing might be needed to reduce community 
transmission until high population-wide coverage is 
achieved with vaccines that provide long-lasting pro-
tection against both disease and infection. Our study 
provides broad insights rather than precise quantitative 
projections given the many uncertainties and unknown 
characteristics of the vaccine candidates and aspects of 
the long-term COVID-19 epidemiology, and the value of 
vaccines will ultimately depend on other policies and 
population behaviours (both economic and health 
related).
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